155 related articles for article (PubMed ID: 31828486)
1. Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.
Bello M; Guadarrama-García C; Rodriguez-Fonseca RA
J Comput Aided Mol Des; 2020 Mar; 34(3):293-303. PubMed ID: 31828486
[TBL] [Abstract][Full Text] [Related]
2. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2.
Martiniano B
J Mol Model; 2021 Mar; 27(4):105. PubMed ID: 33686576
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy.
Gavriil ES; Doukatas A; Karampelas T; Myrianthopoulos V; Dimitrakis S; Mikros E; Marakos P; Tamvakopoulos C; Pouli N
Eur J Med Chem; 2019 Aug; 176():393-409. PubMed ID: 31125894
[TBL] [Abstract][Full Text] [Related]
5. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
[TBL] [Abstract][Full Text] [Related]
6. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
[TBL] [Abstract][Full Text] [Related]
7. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
[TBL] [Abstract][Full Text] [Related]
9. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Yang B; Zhang H; Wang H
J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
[TBL] [Abstract][Full Text] [Related]
10. Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors.
Wang Y; Yin X; Chen L; Yin Z; Zuo Z
Bioorg Chem; 2022 Oct; 127():105868. PubMed ID: 35816874
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
12. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Aertgeerts K; Skene R; Yano J; Sang BC; Zou H; Snell G; Jennings A; Iwamoto K; Habuka N; Hirokawa A; Ishikawa T; Tanaka T; Miki H; Ohta Y; Sogabe S
J Biol Chem; 2011 May; 286(21):18756-65. PubMed ID: 21454582
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
14. Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
Mora Vidal R; Regufe da Mota S; Hayden A; Markham H; Douglas J; Packham G; Crabb SJ
Urology; 2018 Feb; 112():225.e1-225.e7. PubMed ID: 29154981
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
16. Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
Yang B; Yang YS; Yang N; Li G; Zhu HL
Sci Rep; 2016 Jun; 6():27571. PubMed ID: 27273260
[TBL] [Abstract][Full Text] [Related]
17. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Liu Z; Fusi A; Schmittel A; Tinhofer I; Schneider A; Keilholz U
Cancer Biol Ther; 2010 Nov; 10(9):860-4. PubMed ID: 20855957
[TBL] [Abstract][Full Text] [Related]
18. The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells.
Yang Y; Choppavarapu L; Fang K; Naeini AS; Nosirov B; Li J; Yang K; He Z; Zhou Y; Schiff R; Li R; Hu Y; Wang J; Jin VX
Biochim Biophys Acta Gene Regul Mech; 2020 Nov; 1863(11):194631. PubMed ID: 32956836
[TBL] [Abstract][Full Text] [Related]
19. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]